2026 Q3 Portfolio Activity
In 2026 Q3, Spruce Street Capital LP maintained a portfolio of 39 distinct positions. The most significant new addition was ENTERA BIO LTD, now representing 5.19% of the total fund value. They heavily accumulated shares in ZAI LAB LTD, increasing the position by 273.4%. The fund also reduced its exposure to RESEARCH ALLIANCE CORP III by 70.0%.
Position History
hover any row below to update
Loading…
Spruce Street Capital LP
AUM $629M
Total Positions
39
Quarter
2026 Q3
Top Holding
KNSA (10.9%)
Top 10 Concentration
64.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-39 of 39
Spruce Street Capital LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KNSA
KINIKSA PHARMAC...
|
Healthcare | 10.89% | 11.52% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
918,070 | $68,497,203 |
$47.58
+102.4%
|
2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 8.56% | 8.76% |
#2
1
Prev: #3
|
5.4 |
—
|
28,620 | 2.1% |
P
S
|
1,404,779 | $53,863,456 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 8.56% | 10.95% |
#3
1
Prev: #2
|
5.4 |
—
|
no change | no change |
P
S
|
2,984,125 | $53,863,456 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 6.81% | 7.01% |
#4
1
Prev: #5
|
5.7 |
—
|
323,511 | 23.9% |
P
S
|
1,676,558 | $42,802,526 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 6.11% | 5.59% |
#5
2
Prev: #7
|
5.9 |
—
|
404,595 | 74.4% |
P
S
|
948,471 | $38,432,045 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ENTX
ENTERA BIO LTD
|
Healthcare | 5.19% | — |
#6
Prev: #—
|
5.6 |
—
|
11,213,455 | — |
NEW
|
11,213,455 | $32,631,154 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 4.97% | 6.79% |
#7
1
Prev: #6
|
3.0 |
—
|
no change | no change |
P
S
|
354,816 | $31,241,549 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SVRA
SAVARA INC
|
Healthcare | 4.42% | 4.17% |
#8
Prev: #8
|
4.8 |
—
|
1,929,365 | 55.9% |
P
S
|
5,381,941 | $27,770,816 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 4.36% | 1.04% |
#9
15
Prev: #24
|
4.7 |
—
|
763,048 | 273.4% |
P
S
|
1,042,158 | $27,450,442 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 4.14% | 8.68% |
#10
6
Prev: #4
|
3.7 |
—
|
520,863 | 8.1% |
P
S
|
6,912,191 | $26,058,960 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 2.77% | 3.49% |
#11
2
Prev: #9
|
2.1 |
—
|
no change | no change |
P
S
|
306,047 | $17,414,074 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
OBX
OBSIDIAN THERAP...
|
Healthcare | 2.73% | — |
#12
Prev: #—
|
4.6 |
—
|
1,249,943 | — |
NEW
|
1,249,943 | $17,161,717 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 2.40% | 3.28% |
#13
3
Prev: #10
|
2.0 |
—
|
no change | no change |
P
S
|
329,006 | $15,081,635 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 2.28% | 3.11% |
#14
3
Prev: #11
|
1.9 |
—
|
no change | no change |
P
S
|
1,088,731 | $14,349,475 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SRZN
SURROZEN INC
|
Healthcare | 2.21% | 2.20% |
#15
1
Prev: #14
|
1.9 |
—
|
no change | no change |
P
S
|
432,040 | $13,903,047 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 2.20% | — |
#16
Prev: #—
|
4.4 |
—
|
1,400,000 | — |
NEW
|
1,400,000 | $13,832,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
YARW
YARROW BIOSCIEN...
|
Healthcare | 2.17% | — |
#17
Prev: #—
|
4.4 |
—
|
607,382 | — |
NEW
|
607,382 | $13,678,243 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IFRX
INFLARX NV
|
Healthcare | 1.74% | 2.35% |
#18
5
Prev: #13
|
2.7 |
—
|
733,972 | 13.7% |
P
S
|
6,086,170 | $10,955,106 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
KRSA
KORSANA BIOSCIE...
|
Healthcare | 1.64% | — |
#19
Prev: #—
|
4.2 |
—
|
338,951 | — |
NEW
|
338,951 | $10,304,110 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 1.62% | 2.47% |
#20
8
Prev: #12
|
1.6 |
—
|
no change | no change |
P
S
|
3,693,931 | $10,158,310 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ANTX
AN2 THERAPEUTIC...
|
Healthcare | 1.48% | 1.58% |
#21
2
Prev: #19
|
2.6 |
—
|
90,938 | 5.5% |
P
S
|
1,752,011 | $9,320,699 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.17% | 1.43% |
#22
1
Prev: #21
|
1.5 |
—
|
no change | no change |
P
S
|
3,581,603 | $7,360,194 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 1.11% | 1.68% |
#23
5
Prev: #18
|
1.4 |
—
|
no change | no change |
P
S
|
2,198,502 | $6,969,251 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.10% | 1.95% |
#24
8
Prev: #16
|
1.4 |
—
|
no change | no change |
P
S
|
4,059,054 | $6,940,982 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ERAS
ERASCA INC
|
Healthcare | 0.98% | 1.52% |
#25
5
Prev: #20
|
1.4 |
—
|
no change | no change |
P
S
|
422,543 | $6,194,480 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 0.95% | 0.94% |
#26
1
Prev: #25
|
1.4 |
—
|
no change | no change |
P
S
|
736,637 | $5,959,393 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 0.88% | 1.80% |
#27
10
Prev: #17
|
1.4 |
—
|
no change | no change |
P
S
|
1,655,500 | $5,545,925 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
N/A
RESEARCH ALLIAN...
|
|
Unknown | 0.86% | 1.05% |
#28
6
Prev: #22
|
1.3 |
—
|
no change | no change |
P
S
|
500,000 | $5,415,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
N/A
RESEARCH ALLIAN...
|
|
Unknown | 0.86% | — |
#29
Prev: #—
|
3.8 |
—
|
450,000 | — |
NEW
|
450,000 | $5,400,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 0.84% | 1.04% |
#30
7
Prev: #23
|
1.3 |
—
|
no change | no change |
P
S
|
500,000 | $5,310,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
N/A
ATTOVIA THERAPE...
|
|
Unknown | 0.62% | — |
#31
Prev: #—
|
3.7 |
—
|
228,295 | — |
NEW
|
228,295 | $3,912,976 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
ALEC
ALECTOR INC
|
Healthcare | 0.62% | 0.83% |
#32
5
Prev: #27
|
1.2 |
—
|
no change | no change |
P
S
|
2,101,068 | $3,886,976 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
N/A
TCGX ACQUISITIO...
|
|
Unknown | 0.60% | — |
#33
Prev: #—
|
3.7 |
—
|
300,000 | — |
NEW
|
300,000 | $3,753,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.50% | 0.85% |
#34
8
Prev: #26
|
1.2 |
—
|
no change | no change |
P
S
|
928,593 | $3,138,644 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 0.46% | 2.17% |
#35
20
Prev: #15
|
1.2 |
—
|
no change | no change |
P
S
|
392,574 | $2,901,122 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.42% | 0.68% |
#36
7
Prev: #29
|
1.2 |
—
|
no change | no change |
P
S
|
231,585 | $2,667,859 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-13 | |||
|
N/A
JATT II ACQUISI...
|
|
Unknown | 0.29% | 0.36% |
#37
7
Prev: #30
|
1.1 |
—
|
no change | no change |
P
S
|
160,000 | $1,799,200 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
N/A
JATT III ACQUIS...
|
|
Unknown | 0.26% | — |
#38
Prev: #—
|
3.6 |
—
|
150,000 | — |
NEW
|
150,000 | $1,653,000 | — | 13F Filing | 2026-09-30 | 2026-11-13 | ||
|
LONA
LEONABIO INC
|
Healthcare | 0.22% | 0.71% |
#39
11
Prev: #28
|
1.1 |
—
|
no change | no change |
P
S
|
393,701 | $1,405,513 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-13 |
Showing 1-39 of 39 holdings